Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coviro.2021.06.008 http://scihub22266oqcxt.onion/10.1016/j.coviro.2021.06.008 34256351!8238655!34256351     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Virol 2021 ; 50 (ä): 1-7 Nephropedia Template TP {{tp|p=34256351|t=2021. Time to Mind the Gap in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2 |pdf=|usr=}}{{34256351}} gab.com Text Time to Mind the Gap in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2 JO: Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34256351 #FOAvip A pipeline of effective direct-acting antivirals (DAAs) remains a critical gap in addressing the current pandemic given vaccination hesitancy, the emergence of viral variants of concern, susceptible populations for which vaccination is ineffective or unavailable, and the possibility that coronavirus disease 2019 (COVID-19) is here to stay. Since the start of the pandemic, global efforts in small molecule drug discovery have focused largely on testing of FDA-approved drugs to accelerate evaluation in clinical trials in hospitalized patients. With 80% of the population who test positive for SARS-CoV-2 having asymptomatic to mild COVID-19, early stage, DAAs would be of enormous benefit to reduce spread, duration of symptoms and quarantine length. We highlight a few of the most promising DAAs in clinical trials and discuss considerations in how to navigate the challenges and pitfalls of novel small molecule discovery and thereby accelerate the advancement of new, safe, and oral DAAs. Twit Text FOAVip Time to Mind the Gap in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2 ????Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34256351 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34256351 #FOAvip English Wikipedia <ref>{{Cite pmid|34256351}}</ref> Time to Mind the Gap in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2 #MMPMID34256351 Jonsson CB; Golden JE; Meibohm B Curr Opin Virol 2021[Oct]; 50 (ä): 1-7 PMID34256351show ga A pipeline of effective direct-acting antivirals (DAAs) remains a critical gap in addressing the current pandemic given vaccination hesitancy, the emergence of viral variants of concern, susceptible populations for which vaccination is ineffective or unavailable, and the possibility that coronavirus disease 2019 (COVID-19) is here to stay. Since the start of the pandemic, global efforts in small molecule drug discovery have focused largely on testing of FDA-approved drugs to accelerate evaluation in clinical trials in hospitalized patients. With 80% of the population who test positive for SARS-CoV-2 having asymptomatic to mild COVID-19, early stage, DAAs would be of enormous benefit to reduce spread, duration of symptoms and quarantine length. We highlight a few of the most promising DAAs in clinical trials and discuss considerations in how to navigate the challenges and pitfalls of novel small molecule discovery and thereby accelerate the advancement of new, safe, and oral DAAs. |*Drug Discovery[MESH] |Antiviral Agents/*pharmacology[MESH] |Clinical Trials as Topic[MESH] |Critical Pathways[MESH] |Humans[MESH]Time to Mind the Gap in novel small molecule drug discovery for dire(epmc).pdf DeepDyve Pubget Overpricing